1. Home
  2. Companies
  3. RCE
  4. Material Events

Recce Pharmaceuticals (ASX:RCE) — Material Events

ASX:RCE · 20 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 18 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
18
Recce Pharmaceuticals Secures $5.3M R&D Rebate, Advances U.S. Army Burn Wound CollaborationMedium
Recce Pharmaceuticals advances clinical trials, secures U.S. Army collaboration and Brazil patent; receives $5.3M AUD R&D rebate
30 Apr 2026 ·Quarterly Cash Flow Statement & Operational Highlights ·85
Recce Advances Phase 3 Trial and Secures $85M R&D Funding EligibilityMedium
Recce advances Phase 3 trial, secures patent and AUD 5.3M R&D rebate, awarded AUD 85M R&D funding eligibility
30 Jan 2026 ·Quarterly Cash Flow Statement & Operational Highlights ·85
Recce Pharmaceuticals Advances Synthetic Antibiotic RECCE 327 with ASEAN Registration Targeted for 2026Medium
Recce Pharmaceuticals advances Phase 3 trial of novel synthetic antibiotic RECCE 327 targeting multidrug-resistant infections with ASEAN registration planned by 2026
19 Mar 2026 ·Corporate Presentation ·85
Recce Pharmaceuticals Raises A$4 Million to Fuel Licensing and Clinical TrialsMedium
Recce Pharmaceuticals raises A$4 million via placement and launches Share Purchase Plan
26 June 2026 ·Capital Raising ·85
Recce’s RECCE 327 Gel Accelerates Healing in Drug-Resistant Burn WoundsMedium
Recce's RECCE 327 Gel Shows Superior Efficacy in Antibiotic-Resistant Burn Wound Models
12 Aug 2025 ·Clinical Trial Results Announcement ·85
Recce Pharmaceuticals Secures 10-Year Licensing Deal for R327 Gel in MENAMedium
Recce Pharmaceuticals Signs 10-Year Exclusive Licensing Term Sheet for R327 Gel in MENA Region
27 May 2026 ·Licensing Agreement Announcement ·85
Recce Pharmaceuticals Expands Phase 3 Trial for Diabetic Foot Infections with Broader Patient ScopeMedium
Recce Pharmaceuticals advances pivotal Phase 3 trial for diabetic foot infections with expanded patient eligibility
22 June 2026 ·Clinical Trial Update ·85
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Treatment in IndonesiaMedium
Recce Pharmaceuticals Starts Phase 3 Trial Dosing for Diabetic Foot Infections in Indonesia
25 Sept 2025 ·Clinical Trial Update ·85
Recce Pharmaceuticals Secures $15.8M Capital Raise Amid Phase 3 Trial ExpansionMedium
Recce Pharmaceuticals advances clinical trials, secures A$15.8M capital raise and A$30M debt facility
31 July 2025 ·Quarterly Cash Flow Statement & Operational Highlights ·85
Recce Pharmaceuticals Secures A$85M R&D Tax Incentive Boost for Global Antibiotic FightMedium
Recce Pharmaceuticals Secures A$85M Advanced Overseas R&D Tax Incentive for Synthetic Anti-Infective Programs
16 Dec 2025 ·ASX Announcement ·85
Recce Pharmaceuticals Deepens U.S. Army Ties to Combat Burn Wound InfectionsMedium
Recce Pharmaceuticals partners with U.S. Army to advance RECCE 327 Gel for burn wound infections
2 Feb 2026 ·ASX Announcement ·80
Recce’s Inhaled RECCE 327 Slashes Drug-Resistant Pneumonia in Preclinical TestsMedium
Recce Pharmaceuticals' inhaled RECCE 327 shows strong preclinical efficacy against drug-resistant pneumonia bacteria
26 Nov 2025 ·ASX Announcement ·80
Recce Pharmaceuticals Advances Phase 3 Trials Amid Rising LossesMedium
Recce Pharmaceuticals reports increased loss amid Phase 3 trial approvals and strong funding
29 Aug 2025 ·Appendix 4E Final Report ·80
Recce Pharmaceuticals Expands Asian Patent Reach with Hong Kong ApprovalMedium
Recce Pharmaceuticals Secures Hong Kong Patent for Synthetic Anti-Infectives
27 Nov 2025 ·Patent Grant Announcement ·80
Recce Pharmaceuticals Advances Phase 3 Trial Amid Strong Antibacterial DataMedium
Recce Pharmaceuticals advances Phase 3 trial in Indonesia; strong preclinical data and WHO recognition; cash position supported by equity facility extension
31 Oct 2025 ·Quarterly Cash Flow Statement & Operational Highlights ·80
Recce Pharmaceuticals’ Loss Widens as Clinical Trials Advance and Funding SecuredMedium
Recce Pharmaceuticals reports widening loss amid clinical progress and funding support
27 Feb 2026 ·Appendix 4D / Interim Financial Report ·75
Recce Pharmaceuticals Passes Key Indonesian Inspection for Phase 3 Diabetic Foot Infection TrialMedium
Recce Pharmaceuticals clears Indonesian regulatory inspection for Phase 3 diabetic foot infection trial
21 Apr 2026 ·Regulatory Update ·75
Recce Pharmaceuticals Secures Key Patent in Brazil’s Growing Antibiotics MarketMedium
Recce Pharmaceuticals Secures Brazilian Patent for Synthetic Anti-Infectives
24 Mar 2026 ·Patent Grant Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.